News and Events Day: March 19, 2018

Palo Alto, CA-based twoXAR has developed a drug discovery computing platform that it says is faster, less expensive, and more accurate than traditional laboratory approaches. The company claims it can identify drug candidates for testing “in weeks rather than years.” The company adds that the technology has yielded potential drugs in a wide range of diseases including liver cancer, rheumatoid arthritis, and type 2 diabetes.
Traditionally, building a portfolio of drug programs requires hundreds of millions of dollars and takes many years in the biopharmaceutical industry. The convergence of available biomedical data, affordable cloud computing, and advances in algorithms is now enabling companies to build these drug portfolios for an order of magnitude less money and in a fraction of the time it traditionally takes. This is precisely what twoXAR is doing.